Drug Central

Drug results: 14

metformin	A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
glibenclamide	An antidiabetic sulfonylurea derivative with actions similar to those of chlorpropamide.
glipizide	An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
pioglitazone	Pioglitazone is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPAR-gamma). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism.
empagliflozin	Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
sitagliptin	A pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones GLUCAGON-LIKE PEPTIDE-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is used in the treatment of TYPE 2 DIABETES.
canagliflozin	A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
linagliptin	Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. Both incretin hormones are involved in the physiological regulation of glucose homeostasis. Incretin hormones are secreted at a low basal level throughout the day and levels rise immediately after meal intake. GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. Furthermore, GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose output.
alogliptin	a selective, orally bioavailable inhibitor of the enzymatic activity of dipeptidyl peptidase-4 (DPP-4) that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus
dapagliflozin	an Sodium-glucose cotransporter 2 (SGLT2) inhibitor, SGLT2 expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen, by inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion
saxagliptin	inhibits Dipeptidyl Peptidase-4
rosiglitazone	A thiazolidinedione that functions as a selective agonist for PPAR GAMMA. It improves INSULIN SENSITIVITY in adipose tissue, skeletal muscle, and the liver of patients with TYPE 2 DIABETES MELLITUS.
liraglutide	An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.
phenformin	A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)

Featured News

Drugcentral 2023 NAR Article

The Latest in Chemistry in Coronavirus Research

Drugs in the News

Makena Venetoclax Dapagliflozin KEYTRUDA Sacubitril LORBRENA Hydroxychloroquine

DrugCentral Search Overview

Drug search example:

Generic drug names, drug synonyms, trade names terms can be used to search for drugs. Example search for Lipitor can query using either “Atorvastatin” or “Lipitor”.A comprehensive list of drug development codes and salt or ester forms are also stored in the database and can be used as search terms, for example search for "rosuvastatin" the following terms can be used: "rosuvastatin calcium" or "ZD4522".

Disease search example:

Supported disease terms are SNOMED-CT and OMOP vocabulary terms. Disease annotations for drugs approved before 2012 originate from OMOP vocabulary mappings. For drugs approved after 2012 disease annotations are extracted manually from approved drug labels and mapped to SNOMED-CT concepts.

Example search for “Chronic Hepatitis C” returns the list of antiviral drugs indicated to treat “Chronic Hepatitis C” followed by drugs contra-indicated in hepatitis C.

New! Medical (off label) uses suggestion form
Off label Uses Form
New! Substructure Search:
The current update supports chemical substructure searching. Typing a SMILES string in the DrugCentral Substructure search bar launches a chemical substructure search that finds matching compounds in DrugCentral. E.g., N1cnccc1 . SMILES strings can be located on all Drug Cards under "Description".

New! FDA Adverse Event Reporting System:
The 2021 DrugCentral update, we separately calculated FAERS for men and women to enable research on sex differences in drug safety. The 2022 version goes further by computing adverse drug event scores granulated by age: pediatric data (FAERS_PED) covers patients from 1 day to 17 years, and geriatric data (FAERS_GER) focuses on elderly patients over 65 years of age, respectively. Female, Male, Geriatric & Pediatrics. E.g., amfetamine

New! Target Cards:
To perform a target card search enter a Uniprot target Accession ID e.g., P23975. The target cards depict the "Accession", "Swissprot", "Organism", "Gene" & "Target class" followed by "Drug relations" where the drugs "Bioactivity mechanism-of-actions" are identified.

Target search example:
Supported target search terms are HUGO gene symbols, Uniprot accessions and target names, and Swissprot identifiers. Example search for drugs targeting Mu-type opioid receptor can be run using either of the terms: “OPRM1”, P35372, “OPRM_HUMAN”, full or partial Uniprot target name. Returned drugs are ranked using the following criteria: top ranked drugs have mechanism of action target Mu-type opioid receptor, next in the list are drugs with potencies measured against this receptor.

In collaboration with the IDG
New! Veterinary Drugs, Uses & Products:

Drug Central now contains Veterinary Drugs, Uses & Products. The current update adds 1805 bioactivities for 226 veterinary drugs and 804 targets. DrugCentral veterinary data contains application numbers and types, trade names, applicant names, and prescription types for 1492 drug products as referenced in FDA’s Green Book. DrugCentral currently holds 1664 indications (pairs of drug and concept names) for 34 species. Dogs, cattle, and cats sum up to 63% of the indications covered by 193 veterinary drugs. Veterinary Drug Use can be found on each drug card by selecting the sub menu link: 🐶 Veterinary Use on the drug card. E.g., enrofloxacin
Pharmacologic action search example:

Supported pharmacologic action terms are MeSH, FDA [EPC, MoA, PE], ChEBI action roles.

Example search for “HMG-CoA Reductase Inhibitor” FDA EPC term for statin drugs returns list of all statin drugs classified by FDA as HMG-CoA reductase inhibitors.

Ranked result list is annotated with 4 level ranking system ordered from highest to lowest:

A - query term matched drug name or synonyms, mechanism of action target, or drug indication.

B - query term matched disease term in drug contraindications or off-label uses, targets listed in drug bioactivity profiles (not MoA targets), or pharmacologic action descriptions.

C - query term matched short drug description text.

D - query term matched full text in FDA drug labels.

Citing DrugCentral © 2024. License